Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Can-Fite BioPharma Ltd. is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases. The company's lead product, Namodenoson, is in advanced clinical trials for hepatocellular carcinoma and has shown promising results in improving patient outcomes, which positions it uniquely in the oncology market.
Can-Fite primarily aims to monetize its drug pipeline through successful clinical trials leading to product approvals, followed by commercialization. The company has a high gross margin due to the nature of biotech products, but currently lacks revenue generation, placing a heavy reliance on future funding and partnerships.
Clinical trial results for Namodenoson, particularly Phase III outcomes
Regulatory approvals from the FDA or EMA for drug commercialization
Partnership announcements with larger pharmaceutical firms
Market reception and adoption rates of newly approved therapies
Regulatory changes impacting drug approval processes
Technological disruption in drug development methodologies
Emerging therapies from competitors in the oncology space
Potential for generic competition once patents expire
High cash burn rate with no current revenue generation
Dependence on external funding for ongoing clinical trials
low - The demand for biopharmaceuticals is less sensitive to economic cycles, as healthcare spending tends to be more stable.
Interest rates can affect Can-Fite's cost of capital for funding clinical trials and operations, but the company is currently not reliant on debt due to its low debt/equity ratio.
minimal - The company has very low debt levels, which reduces its exposure to credit conditions.
growth - Investors looking for high-risk, high-reward opportunities in biotech will be interested due to the potential upside of successful drug development.
high - The stock has demonstrated significant volatility, particularly given its -86.0% return over the past year.
